The humoral immune response to the inactivated influenza A (H1N1) 2009 monovalent vaccine in patients with Type 2 diabetes mellitus in Korea

Authors

Errata

This article is corrected by:

  1. Errata: Corrigendum Volume 28, Issue 12, 1541, Article first published online: 17 November 2011

Chul Woo Ahn MD PhD, Division of Endocrinology, Department for Internal Medicine, Yonsei University College of Medicine, Gangnam Severance Hospital, 612 Eonjuro, Gangnam-gu, 135-270, Seoul, Korea. E-mail: acw@yuhs.ac

Abstract

Diabet. Med. 28, 815–817 (2011)

Abstract

Aims  We evaluated the antibody response to a single-dose adjuvanted, inactivated, pandemic H1N1 influenza vaccination in patients with diabetes and assessed factors associated with the failure to induce antibody responses.

Methods  Eighty-two patients with Type 2 diabetes were vaccinated and antibody responses were determined with haemagglutination inhibition assay and anti-haemagglutinin antibody ELISA.

Results  Among 70 antibody-negative patients at baseline, 34 (48.6%) achieved seroconversion; 28 (60.9%) in the young adults group and six (25%) in the elderly group acquired H1N1-specific antibodies. Patients in the older age range or with longer duration of diabetes had a lower seroconversion rate.

Conclusions  Our data show low cross-reactive antibody carrying rate and low seroconversion rate in patients with diabetes. Until larger-scale, case-controlled trials become available, older patients and patients with a longer duration of diabetes should be considered for the two-dose vaccination or have antibody titres measured after the first vaccination.

Ancillary